In this Redcliffe Cardiology NVM reflections episode, Prof Nicolas Van Mieghem cuts through the noise from TCT 2025. Tune in to hear what the SELUTION trials mean for drug-coated balloons in de novo disease and ISR, why cost and sizing matter in calcium modification, how PE thrombectomy stacks up against anticoagulation alone, and what 7-year PARTNER 3 and 10-year NOBLE data signal for TAVR and left main PCI. Practical takeaways you can use on your next case.

Drug-coated balloons (DCB): SELUTION-ISR and the large SOLUTION DeNovo RCT show non-inferiority vs contemporary care,with ~80% of DCB cases avoiding a stent. How to size, when to escalate to DES, and why 5-year data will be decisive. We also contrast these results with CAGE-FREE-1 three-year outcomes and discuss “not all DCBs are created equal.”

Calcium strategies: SHORT-CUT and VICTORY pit cutting/high-pressure balloons against intravascular lithotripsy. Similar luminal results—but very different costs and workflow. We outline a toolbox and imaging-first algorithm for nodular/annular calcium and where atherectomy still fits.

Pulmonary embolism: STORM-PE shows catheter thrombectomy on top of anticoagulation cuts RV/LV ratio fast along with real-world procedure times, blood loss, and complications you should counsel up front.

Valves & MR: PARTNER 3 at 7 years TAVR vs surgery outcomes remain similar with reassuring valve durability; mild PVL not tied to mortality. ENCIRCLE (Sapien M3 TMVR) shows strong MR elimination but flags stroke and leaflet thrombosis prompting a rethink of antithrombotic strategy.

Coronary trials: NOBLE 10-year left main results, PROCTOR (native CTO vs SVG PCI), I-MODERN (iFR-guided complete revasc vs deferred CMR), iCABG (physiology-guided grafting), INFINITY SWEDEHEART (bioadaptor stent signals), and ANDES (post-LAAO DOAC vs DAPT).

Expect pragmatic thresholds, device selection tips, and critical review of the latest evidence with Prof Nicolas Van Mieghem.

At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease.

The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption.

01:05 – Tricuspid Therapies

Late-breaking data from Triluminate (TriClip) and Tricend/Evoke: real-world outcomes, bleeding reduction, pacemaker trends, and patient selection.

06:40 – Aortic Valve Durability

PARTNER 7-year outcomes: TAVR vs. SAVR, valve performance over time, implications for younger/lower-risk patients, and evolving device technology.

12:55 – Valvular Disease Prevalence

Insights from the PREVUE-VALVE: first nationwide prevalence data, under-treatment of severe disease, and role of AI in early detection.

17:30 – Mitral Valve Advances

Landmark trials: SUMMIT Trial (MAC population) and first-in-human Sapien M3 transseptal TMVR. Key outcomes, screen failure rates, and implications for clinical adoption.

24:50 – Future of Structural Heart Interventions

Patient-first approach, expanding treatment options, and importance of durability and early diagnosis.

For more content from TCT 2025 head to the Late-breaking Science Video Collection.

Editor: Mirjam Boros

Videographer: Tom Green and Dan Brent

Support: This is an independent video produced by Radcliffe Cardiology.

Explore ESC 25 Top Trials with Insights from the Thoraxcenter!

Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at ESC 2025.

In this comprehensive ESC wrap-up, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions.

00:15 - DOUBLE-CHOICE

04:43 - VANTAGE

07:44 - VICTOR and VICTORIA

11:29 - DIGIT-HF

14:22 - DAPA ACT HF-TIMI 68

16:55 - BETAMI-DANBLOCK and REBOOT-CNIC

22:13 - REFINE-ICD

25:34 - OPTION-STEMI

30:40 - DUAL-ACS

33:05 - NEO-MINDSET

35:58 - TARGET-FIRST

38:54 - OUTREACH

41:50 - FIRE

42:46 - AI-Gatekeeper

45:13 - POTCAST

Expert interventionalists, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve.

ESC Congress 2025 Hot Line Trials Discussed:

00:25 - DOUBLE-CHOICE

03:03 - VANTAGE

05:03 - VICTOR

06:28 - VICTORIA

07:58 - DIGIT HF

10:19 DAPA ACT HF-TIMI 68

12:35 REBOOT-CNIC

14:07 BETAMI DANBLOCK

16:03 REFINE ICD

18:05 OPTION STEMI

20:43 DUAL ACS

22:46 NEO MINDSET

24:53 TARGET FIRST

26:59 OUTREACH

29:29 FIRE

31:40 AI GATEKEEPER

22:42 LAA CLOSURE

Stay tuned for Radcliffe Cardiology’s in-depth coverage of these and other pivotal trials from ESC Congress 2025.

Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran by The Radcliffe Cardiology Podcast

Explore the Top Trials from EuroPCR 25 with Insights from the Thoraxcenter!

Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at EuroPCR.

In this comprehensive EuroPCR review, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions.

00:18 - UK TAVI

03:22 - ACURATE IDE

06:10 - COMPARE TAVI

07:21 - PROTECTED TAVR and BHF PROTECT TAVI Meta Analyses

11:51 - PROVISION

14:35 - REPEAT QFR

16:44 - FAITAVI

19:49 - ILIAS ANOCA

22:20 - CAREER

26:20 - RETRIEVE AMI

28:06 - ICARE-OFDI

32:28 - COMPARE-ABSORB

33:20 - BIOADAPTOR RCT

34:22 - PERFECT PSP

37:34 - bRIGHT

39:40 - TRINITY

41:45 - AMEND

What advice does Dr Ritu Thamman have for female cardiologists trying to navigate power dynamics within the workplace?

Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Dr Ritu Thamman (University of Pittsburgh School of Medicine, PA, US) to discuss the challenges posed by queen bee syndrome and the importance of building networks to feel secure in leadership positions. Together, they also explore how institutions can improve lab safety for interventional cardiologists and pregnant women at higher risk of radiation exposure, and Dr Thamman highlights the huge disparities between standards of protection across the globe. Finally, Dr Thamman offers valuable advice to younger colleagues struggling to create an attainable work-life balance.

What can the transition to industry offer young cardiologists, and should they take the leap?

Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) engage in an inspiring discussion with Interventional Cardiologist, Dr Marta Bande (Boston Scientific Corporation, Milan, IT). The episode dives into Dr Bande's motivations to move to industry after years in clinical practise and the skills and opportunities this exposed her to. As well as providing advice for young cardiologists contemplating changing career paths, Dr Bande talks on navigating career struggles and why she actively promotes diversity for women within cardiology.

How can institutions overcome toxic workplace behaviours, and why is it important?

Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Mamas Mamas (University of Keele, Staffordshire, UK) to discuss how we can achieve equity in the workplace. Together, they share insights on the dangers of tall poppy syndrome, how to recognise our biases, and why many feel unable to call out bullying and harassment. Prof Mamas also highlights the responsibility of institutions and leadership to implement a code of conduct, framework for independent reporting of uncivil behaviours, and implications if these are not met.

What is the reasoning behind the porosity of data when it comes to CV outcomes in women?

Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Barbara Casadei (British Heart Foundation, University of Oxford, Oxford, UK) who offers her advice to young cardiologists who aren't receiving the recognition they deserve. As the first female president of the ESC, Prof Casadei discusses how to navigate challenges in leadership roles and her thoughts on recent society statements against toxic behaviours in the workplace. Lastly, she explores how to achieve gender equity in clinical trial research.